Innovata Biomed in Japanese drug delivery deal:
This article was originally published in Clinica
Innovata Biomed (IB), the respiratory drug delivery subsidiary of Warrington, UK-based ML Laboratories, has signed an agreement with Japanese healthcare company Otsuka Pharmaceutical Co. Under the terms of the agreement, the Tokyo-based company has been given an exclusive licence to market its asthma treatment product, Meptin, in IB's "Clickhaler" dry powder inhaler in Japan and Spain. In return, IB will receive milestone payments and will supply the inhalers to Otsuka. "We strongly believe that this combinations will provide asthma patients with the most reliable, easy-to-use solution," said Otsuka's operations officer Masuhiro Yoshitake. Paul Bellington, managing director of St. Albans-based IB, added: "Today's announcement supports Innovata Biomed's position as one of the leading independent providers of respiratory drug delivery technologies to the pharmaceuticals industry."
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.